

REMARKS

Support for the present amendments to the specification can be found in the application as originally filed.

The change from “ μm BSO” to “ μM BSO” in two paragraphs simply corrects a typographical error in these two places. The “ μM BSO” is correct elsewhere in these paragraphs.

On page 9 of the originally filed PCT application (PCT/JP00/02763), the symbols for the data points for different cell types are shown, along with the name of the cell line in Latin characters. The symbols were inadvertently dropped in the text of the specification in the translation.

Applicants respectfully submit that the presence of the names of the cell lines in Latin characters in the original PCT application, when combined with the translation of the specification, would be sufficient to elucidate the figures to one of ordinary skill in the art. Therefore, Applicants respectfully request the Examiner to amend the specification accordingly.

Conclusion


In view of the foregoing amendments and remarks, the present application is respectfully considered in condition for allowance. An early reconsideration and notice of allowance are earnestly solicited.

It is believed that all outstanding rejections have been addressed by this submission and that all the claims are in condition for allowance. If discussion of any amendment or remark made herein would advance this important case to allowance, the Examiner is invited to call the undersigned as soon as convenient.

If a petition for an additional extension of time is required, then the Examiner is requested to treat this as a conditional petition for an additional extension of time. Although it is not believed that any additional fee is required to consider this submission, the Commissioner is hereby authorized to charge our deposit account no. 04-1105 should any fee be deemed necessary.

Respectfully submitted,

Date: July 11, 2003



Kathryn A. Piffat, Ph.D. (Reg. No. 34,901)
EDWARDS & ANGELL, LLP
P.O. Box 9169
Boston, Massachusetts 02209
Telephone: 617-439-4444

APPENDIX I

REVISIONS OF THE SPECIFICATION PURSUANT TO REVISED RULE § 1.121

In the Specification:

Please replace the paragraph on page 12, lines 3-7, with the following paragraph:

--FIG. 1 shows the results by the MTT assay method relating to expression of cytotoxicity of acetaminophen shown in EXAMPLE 4, wherein symbols \square -, \triangle -, \bullet - and \blacktriangle - denote HepG2, Hepc/2E1.3-8, HepG2 + 100 μM BSO and Hepc/2E1.3-8 + 100 μM BSO, respectively.--

Please replace the paragraph on page 12, lines 8-12, with the following paragraph:

--FIG. 2 shows the results by the LDH leakage test on expression of cytotoxicity of acetaminophen shown in EXAMPLE 4, wherein symbols \square -, \triangle -, \bullet - and \blacktriangle - denote HepG2, Hepc/2E1.3-8, HepG2 + 100 μM BSO and Hepc/2E1.3-8 + 100 μM BSO, respectively.--

Please replace the paragraph on page 12, lines 13-16, with the following paragraph:

--FIG. 3 shows the results by the MTT assay method relating to expression of cytotoxicity of benzantracene shown in EXAMPLE 5, wherein symbols \square - and \bullet - denote HepG2 and Hepc/1A1.4, respectively.--

Please replace the paragraph on page 12, lines 17-20, with the following paragraph:

--FIG. 4 shows the results by the MTT assay method relating to expression of cytotoxicity of cyclophosphamide shown in EXAMPLE 6, wherein symbols \square - and \bullet - denote HepG2 and Hepc/2B6.68, respectively.--

Please replace the paragraph on page 12, lines 21-24, with the following paragraph:

FIG. 5 shows the results by the LDH leakage test on expression of cytotoxicity of cyclophosphamide shown in EXAMPLE 6, wherein symbols \square - and \square - denote HepG2 and Hepc/2B6.68, respectively.--

Please replace the paragraph on page 12, lines 25-27, with the following paragraph:

--FIG. 6 shows the results of the test on inhibition of ketoconazole against the CYP3A4 activity shown in EXAMPLE 7, wherein symbol -□- denotes ketoconazole.--